Survodutide

Buy Survodutide – >99% Purity | GCGR/GLP-1R Dual Agonist | Research Use Only

Survodutide (also known as BI 456906) is a synthetic 29-amino acid dual agonist of the glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R), and one of the most clinically advanced compounds in metabolic and obesity research today. Buy Survodutide in the UK from Peptides Lab UK with >99% HPLC-verified purity, batch-specific COA, and fast UK dispatch for laboratory and in-vitro research use only.

What is Survodutide?

Survodutide (BI 456906) is a 29-amino acid synthetic peptide developed by Boehringer Ingelheim, derived from glucagon with the incorporation of potent GLP-1 receptor activity. It contains a C18 diacid chain that mediates albumin binding, extending its plasma half-life to support once-weekly dosing in research models.

What distinguishes Survodutide from other compounds in this class is its dual receptor engagement — simultaneously activating both the glucagon receptor (GCGR) and the GLP-1 receptor (GLP-1R). This dual mechanism allows researchers to study two complementary and reinforcing pathways at once: GLP-1R agonism reduces appetite and food intake, while GCGR agonism increases energy expenditure and promotes fat metabolism in the liver. Together, this creates a more potent metabolic effect than GLP-1 receptor agonism alone.

Survodutide is currently in Phase 3 clinical trials (SYNCHRONIZE programme), making it one of the most clinically well-validated research peptides currently available from UK peptides suppliers.

How Does Survodutide Work?

Survodutide functions through balanced co-agonism of two key metabolic receptors:

GLP-1 Receptor (GLP-1R) Activation:

• Suppresses appetite and reduces caloric intake through central satiety signalling
• Slows gastric emptying, prolonging the sensation of fullness
• Promotes insulin secretion in a glucose-dependent manner
• Reduces post-meal glucose excursions

Glucagon Receptor (GCGR) Activation:

• Increases energy expenditure through hepatic and thermogenic pathways
• Promotes fatty acid oxidation and lipolysis in the liver
• Increases circulating FGF21 — a metabolic hormone linked to fat burning and insulin sensitivity
• Upregulates liver NNMT mRNA expression, a validated biomarker of GCGR engagement
• Adds a catabolic energy-expenditure component absent in GLP-1 mono-agonists such as semaglutide

The result is a compound that addresses both sides of the energy balance equation in research models — reducing intake via GLP-1R and increasing expenditure via GCGR — making it one of the most mechanistically complete metabolic research tools available.

What Does Survodutide Do in Research?

In pre-clinical and clinical research models, Survodutide has demonstrated a broad range of metabolically significant effects:

• Superior body weight reduction — Phase 2 data demonstrated mean bodyweight reductions approximately 5× greater than placebo at 4.8 mg weekly over 46 weeks, with over half of participants reaching ≥15% bodyweight reduction

What Do Studies Say About Survodutide?

Survodutide has one of the most robust published research profiles of any compound in its class:

• le Roux CW et al. (2024) — The Lancet Diabetes & Endocrinology, 12(3): 162–173 — Landmark Phase 2 randomised, double-blind, placebo-controlled trial across 43 centres in 12 countries. In adults with BMI ≥27 kg/m² without diabetes, Survodutide 4.8 mg once weekly produced mean bodyweight reductions approximately 5× greater than placebo over 46 weeks, with >50% of participants achieving ≥15% bodyweight reduction. DOI: 10.1016/S2213-8587(23)00356-X

What is Survodutide Used For in Research?

• Dual GCGR/GLP-1R receptor binding, activation, and co-agonism studies
• Obesity and metabolic syndrome pre-clinical and in-vitro models
• Energy expenditure and fatty acid oxidation pathway research
• Type 2 diabetes and glycaemic control investigation
• Liver steatosis, MASLD, and MASH model studies
• Cardiovascular metabolic risk and cardiac energy metabolism research
• FGF21 and NNMT as pharmacodynamic biomarkers of GCGR engagement
• Comparative dual agonist research alongside tirzepatide, mazdutide, and pemvidutide
• Structure–activity relationship (SAR) studies within the incretin mimetic class
• Chronic kidney disease and cardiometabolic risk interaction studies

Survodutide vs Other Metabolic Research Peptides

Survodutide’s unique GCGR engagement makes it the preferred research tool when studying the hepatic and energy expenditure components of metabolic disease, which GLP-1 mono-agonists do not fully address.

Quality & Purity Assurance

Every batch of Survodutide from Peptides Lab UK is:

• >99% pure — HPLC and mass spectrometry verified
• Supplied with a full Certificate of Analysis (COA) on request
• Lyophilised powder for maximum stability and long shelf life
• Manufactured under strict, controlled laboratory conditions
• Consistent batch-to-batch quality for reproducible research results

Why Buy Survodutide from Peptides Lab UK?

When you buy Survodutide in the UK from Peptides Lab UK, you receive:

99% purity, HPLC and MS verified, third-party tested

• Full COA documentation per batch
• Fast same-day UK dispatch with tracked delivery
• Competitive pricing with bulk research discounts available
• Trusted by researchers across the UK and Europe